MedTrace Logo

Study of Gemcitabine and Abraxane for Pancreas Cancer

NCT02242409 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2017-02-14

No results posted yet for this study

Summary

A Phase II trial of gemcitabine plus nab-paclitaxel in the second line setting

Conditions

Interventions

DRUG

Gemcitabine and Abraxane

Gemcitabine 1000 mg/m2 followed by abraxane 125 mg/m2 administered intravenously on days 1, 8, and 15 every 28 days

Sponsors & Collaborators

  • Georgetown University

    lead OTHER

Principal Investigators

  • Michael Pishvaian, MD PhD · Georgetown University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02242409 on ClinicalTrials.gov